DelveInsight’s, “Refractory Multiple Myeloma Pipeline Insight 2024” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Refractory Multiple Myeloma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Refractory Multiple Myeloma Research. Learn more about our innovative pipeline today! @ Refractory Multiple Myeloma Pipeline Outlook
Key Takeaways from the Refractory Multiple Myeloma Pipeline Report
- In October 2024:- Ontario Clinical Oncology Group (OCOG)- A phase II study of single agent elranatamab in patients with relapsed and/or refractory multiple myeloma (MM) who have previously received at least three classes of therapeutic agents and are refractory to the last line of treatment. The primary objective of this study is to improve the tolerability and safety of elranatamab in patients with relapsed and/or refractory multiple myeloma by evaluating an outpatient and intermittent dosing strategy.
- In October 2024:- Janssen Research & Development, LLC- The purpose of this study is to identify preventive treatments that can minimize the occurrence, severity, and duration of talquetamab-related distorted taste (dysgeusia), during the prophylaxis (preventive) treatment phase, and to better characterize the signs or symptoms of talquetamab-related distorted taste.
- In October 2024:- BeiGene-A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma. Study consists of two parts, a part 1 dose escalation and a part 2 cohort expansion in combination with dexamethasone and carfilzomib intravenously across two cohorts with a monotherapy component as well.
- In October 2024:- Keymed Biosciences Co.Ltd- This is a multi-center, open-label, Phase 1/2 study in China to evaluate the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics and immunogenicity of CM336 in patients with relapsed or refractory multiple myeloma. This study consists of a dose escalation part (Phase 1) and a dose extension part (Phase 2 ). The safety and tolerability of CM336 will be evaluated in Phase 1 study, as well as the maximum tolerated dose (MTD) and the recommended dose level for Phase 2 study will be determined. The efficacy of CM336 will be evaluated in Phase 2 study.
- In October 2024:- AstraZeneca- This is a Phase I/II, modular, open-label, multicenter, dose escalation, and dose expansion/optimization study to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary efficacy of AZD0305 in participants with RRMM.
- In October 2024:- Kite, A Gilead Company- The goal of this study (iMMagine-3) is to compare the study drug, anitocabtagene autoleucel to standard of care therapy (SOCT) in participants with relapsed/refractory multiple myeloma who have received 1 to 3 prior lines of therapy, including an anti-CD38 monoclonal antibody and an immunomodulatory drug. The primary objective of this study is to compare the efficacy of anitocabtagene autoleucel versus SOCT in participants with RRMM as measured by progression-free survival (PFS) per blinded independent review committee (IRC).
- DelveInsight’s Refractory Multiple Myeloma pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for Refractory Multiple Myeloma treatment.
- The leading Refractory Multiple Myeloma Companies such as MorphoSys, Janssen Research & Development, LLC, Rapa Therapeutics, Novartis, AbbVie, MiNK Therapeutics, AbbVie, Amgen, Gracell Biopharmaceuticals, Inc., Zhejiang ACEA Pharmaceutical Co. Ltd., Allogene Therapeutics, Beijing InnoCare Pharma Tech Co., Ltd., Takeda, Novartis Pharmaceuticals, and others.
- Promising Refractory Multiple Myeloma Therapies such as Isatuximab SC-OBDS, Montelukast, Dexamethasone, Elotuzumab, Iberdomide, Elranatamab injection, Selinexor, Bortezomib, and others.
Stay informed about the cutting-edge advancements in Refractory Multiple Myeloma treatments. Download for updates and be a part of the revolution in cancer care @ Refractory Multiple Myeloma Clinical Trials Assessment
Refractory Multiple Myeloma Emerging Drugs Profile
- Felzartamab: MorphoSys
Felzartamab is an investigational human monoclonal antibody developed using MorphoSys’ HuCAL® antibody technology. The antibody targets against CD38 present on the surface of multiple myeloma cells. The drug candidate uses antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) for tumor cell killing. Currently it is in Phase III stage of clinical trial evaluation to treat Refractory Multiple Myeloma.
- RAPA-201: Rapa Therapeutics
RAPA-201 It is a type of autologous cell therapy. The drug candidate is gene transference, T lymphocyte replacements and work on the same mechanism of action. Currently the drug is being evaluated in Phase II for the treatment of Refractory Multiple Myeloma.
- PHE885: Novartis
PHE885 is an autologous, fully human, BCMA-directed CAR T-cell therapy being developed by Novartis for the treatment of refractory multiple myeloma. It is administered through intravenous route. The therapeutic candidate consists of autologous T cells that are genetically modified to express chimeric antigen receptor that targets BCMA (B-cell maturation antigen). Currently it is in Phase II stage of clinical trials.
- ABBV 453: AbbVie
ABBV-453 is an investigational drug candidate being developed for the treatment of relapsed or refractory multiple myeloma. It is administered through oral route as tablet formulation. It acts by targeting B-cell lymphoma 2 (BCL-2) protein. Currently the drug is in Phase I stage of clinical trials.
Learn more about Refractory Multiple Myeloma Drugs opportunities in our groundbreaking Refractory Multiple Myeloma research and development projects @ Refractory Multiple Myeloma Unmet Needs
Refractory Multiple Myeloma Companies
MorphoSys, Janssen Research & Development, LLC, Rapa Therapeutics, Novartis, AbbVie, MiNK Therapeutics, AbbVie, Amgen, Gracell Biopharmaceuticals, Inc., Zhejiang ACEA Pharmaceutical Co. Ltd., Allogene Therapeutics, Beijing InnoCare Pharma Tech Co., Ltd., Takeda, Novartis Pharmaceuticals, and others
Refractory Multiple Myeloma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
Refractory Multiple Myeloma Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
Discover the latest advancements in Refractory Multiple Myeloma treatment by visiting our website. Stay informed about how we’re transforming the future of oncology @ Refractory Multiple Myeloma Market Drivers and Barriers, and Future Perspectives
Scope of the Refractory Multiple Myeloma Pipeline Report
- Coverage- Global
- Refractory Multiple Myeloma Companies- MorphoSys, Janssen Research & Development, LLC, Rapa Therapeutics, Novartis, AbbVie, MiNK Therapeutics, AbbVie, Amgen, Gracell Biopharmaceuticals, Inc., Zhejiang ACEA Pharmaceutical Co. Ltd., Allogene Therapeutics, Beijing InnoCare Pharma Tech Co., Ltd., Takeda, Novartis Pharmaceuticals, and others.
- Refractory Multiple Myeloma Therapies- Isatuximab SC-OBDS, Montelukast, Dexamethasone, Elotuzumab, Iberdomide, Elranatamab injection, Selinexor, Bortezomib, and others.
- Refractory Multiple Myeloma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Refractory Multiple Myeloma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Refractory Multiple Myeloma Pipeline on our website @ Refractory Multiple Myeloma Emerging Drugs and Companies
Table of Content
- Introduction
- Executive Summary
- Multiple Myeloma: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Late Stage Products (Phase III)
- Comparative Analysis
- Felzartamab: MorphoSys
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- RAPA-201: Rapa Therapeutics
- Early Stage Products (Phase I )
- Comparative Analysis
- ABBV 453: AbbVie
- Inactive Products
- Refractory Multiple Myeloma Key Companies
- Refractory Multiple Myeloma Key Products
- Refractory Multiple Myeloma- Unmet Needs
- Refractory Multiple Myeloma- Market Drivers and Barriers
- Refractory Multiple Myeloma- Future Perspectives and Conclusion
- Refractory Multiple Myeloma Analyst Views
- Refractory Multiple Myeloma Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/